StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Sign in to jot down a private note about CTXR. Only you ever see it.
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
External sites have their own terms, paywalls, and accuracy standards. Stonvex doesn't endorse the content there.
Three bull points, three bear points, and one “what would change my mind” line — both sides forced onto one screen as a research note rather than a tip sheet.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $0.67 | $0.72 | +7.48% | 1.6M |
| 05-15 | $0.73 | $0.70 | -4.05% | 0.7M |
| 05-18 | $0.57 | $0.53 | -7.51% | 2.6M |
| 05-19 | $0.55 | $0.55 | +0.76% | 0.8M |
| 05-20 | $0.55 | $0.58 | +5.45% | 0.9M |
Next report date, year-over-year trend, and recent quarter history.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Each factor shows CTXR's percentile within the scored universe — observational ranking, not a recommendation.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2026 (Est.) Expected 2026-08-10 | Annual 2022 2022-09-30 | Q2 2022 2022-06-30 | Annual 2021 2021-09-30 | Q2 2021 2021-06-30 |
|---|---|---|---|---|---|
Revenue | $15.10M | $90.00K | $90.00K | $90.00K | $90.00K |
Operating Income | Not available | $-33.32M | $-25.77M | $-23.53M | $-18.33M |
Net Income | Not available | $-33.64M | $-25.65M | $-23.05M | $-18.09M |
EPS (Diluted) | $-0.01 | $-0.23 | $-0.18 | $-0.23 | $-0.20 |
Total Assets | Not available | $114.00M | $120.32M | $142.43M | $146.59M |
Total Liabilities | Not available | $10.57M | $9.98M | $9.65M | $9.31M |
Cash & Equivalents | Not available | $41.71M | $48.04M | $70.07M | $115.66M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | $-24.26M | $-18.67M |
Shares Outstanding | Not available | 146.21M | 146.13M | 145.98M | 145.98M |
CTXR is in the extended universe. We surface dollar-volume + price-change percentiles for every US-listed name, but the full 6-factor DNA breakdown (momentum, news, sentiment, flow, relative strength) is only computed on the curated 1137-name primary list.
DNA analysis is not available for this ticker.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.